Fermer le menu

 

 

  • CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia
  • Final European Commission decision expected by June 2025; UK regulatory submission
    foreseen via MHRA’s international recognition procedure
  • AVEROA seeking strategic commercial partners to bring XOANACYL to market across Europe

 

 

Read the press release

Plus d'infos